Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2020

Feb 08, 2021

SELL
$25.24 - $43.45 $5,123 - $8,820
-203 Closed
0 $0
Q1 2020

May 12, 2020

SELL
$18.22 - $28.25 $728 - $1,130
-40 Reduced 16.46%
203 $4,000
Q3 2019

Oct 22, 2019

BUY
$26.11 - $32.99 $1,775 - $2,243
68 Added 38.86%
243 $6,000
Q1 2019

Apr 15, 2019

BUY
$24.82 - $32.54 $4,343 - $5,694
175 New
175 $5,000

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $269M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Flagship Harbor Advisors, LLC Portfolio

Follow Flagship Harbor Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Flagship Harbor Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Flagship Harbor Advisors, LLC with notifications on news.